Skip to content
MarketScale
‹ Back to IndustriesHealthcare

DESIGN TRANSFER: A PROCESS NOT A SINGULAR EVENT

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process….

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

In the development process for medical devices, there comes a point when products transfer from design to production. Often this step doesn’t go as smoothly as it should and the project budget and schedule are adversely impacted. Companies may view design transfer as a one-time event, rather than an essential part of an ongoing process.

During the product development process, the Research and Development (R&D) team is under a tight deadline. They may not have the necessary resources or take sufficient time to create proper documentation. Team members may need to make decisions quickly without fully considering how they could take proactive steps to ensure design transfer will go more smoothly. Subject matter experts on the team may only focus on critical design decisions required to make the product work, without regard for manufacturing. Let’s take a look at some ways to improve design transfer.

Look at Design Transfer as a Process Rather than a Single Event

Design transfer is an integral part of the product development process, from conception through final manufacture. Highly reliable, cost-efficient medical devices require proper design transfer, and that starts with Design for Manufacturability (DFM) and Design for Manufacturing and Assembly (DFMA). In DFM and DFMA the focus is not only on the design itself, but also on the assembly method, ensuring manufacturing readiness for building Beta units, pre-production clinical units, and the pilot program. When the R&D team considers these factors and performs in-process testing, it can significantly improve product quality and reduce the overall cost of manufacturing.

Using DFMA 

The goal of DFMA is simple: to transfer product design into viable, robust production methods. To succeed, the team must establish and maintain procedures that ensure the device design translates into production specifications, including final test acceptance. The transfer should negate and/or identify remaining risks such as single-sourcing, long lead items, build timelines, and line/tooling capacity.

A Design Ready for Transfer:

  • Can be built reliably using known and proven manufacturing and assembly processes
  • Includes supporting cell/line qualifications through manufacturing validations such as Operational Qualification (OQ) and Performance Qualification (PQ)
  • Specifies and documents any inspection aids, assembly fixtures, and custom tools required for manufacture
  • Confirms completed agency testing and production target hardware meets regulatory requirements such as FDA, UL, and CE
  • Includes a complete product Bill of Material (BOM) that has been fully costed up to the customer Stock Keeping Unit (SKU) level
  • Includes packaging, labeling, and Instructions for Use (IFU)

At Sunrise Labs, we see Design Transfer as an integral process beginning early in the life of a product with many crucial steps for success. Communication between key stakeholders early and often is critical to turn innovative ideas into commercial medical devices.

Read more at sunriselabs.com

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Medicare sets $137.53 maximum add-on payment per eligible inpatient case for CT triage AI

Medicare sets $137.53 maximum add-on payment per eligible inpatient case for CT triage AI

Medicare has announced a maximum add-on payment of $137.53 per eligible inpatient case for the use of AI in CT triage, utilizing Aidoc’s CT Body triage technology. This move emphasizes the importance of workflow integration, governance, and coding in hospitals employing radiology AI. The new technology add-on payment (NTAP) signifies a clear investment in AI-driven healthcare solutions.

  • 01Medicare introduces a $137.53 per-case payment for AI in CT triage.
  • 02Hospitals must integrate AI with proper workflow, governance, and coding.
  • 03The NTAP reflects investment in radiology AI solutions.

Aug 30, 2026

Rasonque’s 13.2-month survival result is about to hit hospital formularies

Rasonque’s 13.2-month survival result is about to hit hospital formularies

FDA has cleared Revolution Medicines' drug Rasonque for treating metastatic pancreatic adenocarcinoma. Hospitals are now integrating this drug into their formularies, focusing on operations like pathways, genotyping, and specialty pharmacy flow.

  • 01Rasonque has received FDA clearance for treating metastatic pancreatic adenocarcinoma.
  • 02Hospitals are working on integrating Rasonque into their formularies.
  • 03Operational focus includes pathways, genotyping, and specialty pharmacy flow.

Aug 30, 2026

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Real-time radiation dose tracking is moving from badges to live dashboards in procedure rooms

Radiation Detection Company has introduced a live radiation dose tracking system called Radiant that updates every 0.2 seconds. GE HealthCare has developed browser-based imaging access for hospitals, transforming how radiation monitoring is managed in procedure rooms. This advancement in live dashboards is enhancing real-time monitoring capabilities in healthcare facilities.

  • 01Radiation Detection Company's Radiant updates radiation dose data every 0.2 seconds.
  • 02GE HealthCare has developed browser-based imaging access for better hospital management.
  • 03Live dashboards are transforming radiation monitoring in procedure rooms.

Aug 30, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512